Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized trial of propacetamol vs dexibuprofen for acute upper respiratory tract infection
KCT0002888Phase 3
Key facts
- Status
- Completed
- Start
- Jul 2013
- Countries
- 1
- Sponsor
- Yungjin Pharm. Co., Ltd.
- Modality
- Small Molecules
- Drugs
- propacetamol
- Conditions
- upper respiratory infection (URI)
01
Overview
Phase 3, randomised, double-blind trial of propacetamol in upper respiratory infection (URI) (2 arms), sponsored by Yungjin Pharm. Co., Ltd. Started Jul 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Propacetamol arm
Participants receive propacetamol monotherapy for symptomatic treatment of acute upper respiratory tract infection.
Dexibuprofen arm
Participants receive dexibuprofen monotherapy as active comparator for symptomatic treatment of acute upper respiratory tract infection.
Beyond the preview
Go deeper on KCT0002888.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002888.